Kornimate/medical-research-clean huggingface dataset:
clinical decision support system for remote monitoring of cardiovascular disease patients

Conditions: Decision Support Systems, Clinical

Summary: cardiovascular diseases (cvd) are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. the reduction of cvd-related mortality and morbidity is a key global health priority. cardiac rehabilitation (cr) is a multi-factorial and comprehensive intervention in secondary prevention, being recommended in international guidelines. core components in cr include patient assessment, physical activity counseling, nutritional counseling, risk factor control, patient education, and psychosocial management. cr has been shown to reduce mortality, hospital readmissions, costs, as well as to improve physical fitness, quality of life, and psychological well-being. however, despite the recommendations and proven benefits, acceptance and adherence remain low. access to health technologies in all primary and secondary healthcare facilities can be essential to ensure that those in need receive treatment and counseling. using mobile health (mhealth) solutions may contribute to more personalized and tailored patient recommendations according to their specific needs. also, these technologies contribute to increasing the flexibility, quality, and efficiency of the services provided by health institutions. time constraints, patient overpopulation, and complex guidelines require alternative solutions for real-time patient monitoring. rapidly evolving e-health technology combined with clinical decision support systems (cdss) provides an effective solution to these problems. there are several computerized cdss for managing chronic diseases; however, to the best of our knowledge, there are none for the e-management of patients with cvd. the purpose of this transdisciplinary research project is to develop and evaluate a user-friendly, comprehensive cdss for remote monitoring of cvd patients. the cdss will suggest a monitoring plan for the patient, advise the mhealth tools (apps and wearables) adapted to patient needs, and collect data. the primary outcome will be the reduction of recurrent cardiovascular events (a composite of cardiovascular rehospitalization or urgent consultation, unplanned revascularization, cardiovascular mortality, or worsening heart failure).


Eligibility criteria:
inclusion criteria: * patients attending the cardiology outpatient clinics after the onset of acute cardiac event or * patients attending the cardiology outpatient clinics who are engaged in a structured cardiac rehabilitation program * be able to communicate with the researcher exclusion criteria: * participants will be excluded if they have new york heart association class iii/iv heart failure, terminal disease, or significant non-cardio vascular disease exercise limitations.

Keywords: decision support systems, clinical telemedicine cardiac rehabilitation
evaluation of immunogenicity and safety of varivax™ new seed process (nsp) in children (v210-063)

Conditions: Varicella

Summary: this study will evaluate the immunogenicity, safety, and tolerability of varivax™ (varicella virus vaccine live) manufactured with a new seed process (nsp) compared with the varivax™ 2007 process. the primary hypotheses being tested are that antibody response rate and mean antibody titer induced at 6 weeks after a single vaccination by varivax™ nsp are non-inferior to those induced by varivax™ 2007 process, and that antibody response rate induced by varivax™ nsp is acceptable.


Eligibility criteria:
inclusion criteria: * negative clinical history for varicella, herpes zoster, measles, mumps, and rubella exclusion criteria: * received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study * any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity * received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study * history of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of varivax™ or m-m-r ii™ * received salicylates within 14 days prior to study vaccination * exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination * received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination * history of seizure disorder, including febrile seizure * fever illness (\>=102.2 °f \[39.0 °c\] within 72 hours prior to study vaccination * history of thrombocytopenia * born to a human immunodeficiency virus (hiv)-infected mother * participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.
relationship between chronic non-specific neck pain and lumbar reposition sense

Conditions: Chronic Non-specific Neck Pain

Summary: to investigate the correlation between chronic non-specific neck pain and lumbar reposition sense.

around 67% of people on the planet may at some point in their lives experience chronic, non-specific neck pain. people who have chronic pain frequently need medical services and medications for pain treatment, and there is a link between their functional limitations and disabilities. cervical pain without a recognized clinical reason for the complaints is classified as chronic non-specific neck pain. some symptoms include weakening in the neck muscles and reduced mobility of the cervical spine. "pain perceived anywhere in the posterior region of the cervical spine, from the superior nuchal line to the first thoracic spinous process" is how the international association for the study of pain (iasp) characterized chronic non-specific neck pain. individuals who experience unilateral or central neck discomfort are said to have persistent non-specific neck pain. there will be restricted range of motion in the neck, which frequently re-creates the symptoms; referred shoulder girdle or upper extremity pain may also be felt. patients may also get cervicogenic headaches (cgh). spine position, stability, and movement are all governed by motor control, which results from the ongoing interaction of sensory inputs, such as proprioception, on different neural system levels, and motor outputs to effectors, such as paraspinal muscles. the capacity to precisely position the trunk at predefined points along the sagittal plane's range of motion is known as trunk position sense. trunk repositioning protocols may be a valuable tool for measuring trunk control since they demand that participants precisely move and control the flexing trunk. the most popular criterion for assessing proprioceptive senses is joint repositioning errors. by first generating a target angle or joint location using position or movement sensors, then having the subject represent that place, the test examines the discrepancy between the initial target location and the location realised by the subject.

Eligibility criteria:
inclusion criteria: 1. male and female patients,18-50 years old 2. neck pain continued for at least the last 12 weeks 3. normal body mass index ranged from 18.5 to 24.9 exclusion criteria: 1. radiated neck pain 2. neck pain associated with vertigo 3. a history of surgery on the lower limbs or back 4. back or lower extremity trauma within the last three months. 5. neurological or vestibular disorders 6. diagnosed psychological disorders 7. vertebral fractures 8. metal spine implants 9. tumors 10. diagnosed metabolic diseases 11. using medications that could have an impact on balance in the 24 hours before to the study 12. previous neck surgery 13. red flags (night pain, severe muscle spasms, sudden loss of weight) 14. physiotherapeutic treatment continued in the last 3 months 15. pregnancy, including six months postpartum 16. a diagnosed psychiatric disorder or severe cognitive impairment
hemodynamic changes and vascular tone control after bariatric surgery

Conditions: Systemic Vascular Resistance

Summary: obese patients have increased cardiovascular risk and target organ damage (tod) as compared to people with normal weight. weight loss reduces cardiovascular risk and tod. these changes have been associated mainly to changes in inflammatory and pro-atherogenic markers. office peripheral blood pressure (bp) appears to decrease after bariatric surgery, but information on changes in 24h-ambulatory-bp-monitoring (24h-abpm) and central-bp(cbp), or about the possible role of renin-angiotensin-aldosterone (raas), serotonin(sts) and endocannabinoid(ecs) systems is scarce. our hypothesis is that the hemodynamic changes mediated by alterations in the raas, sts and ecs after weight loss are also responsible for the reduction of tod.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 - 65 years, 2. who have medical indication for treatment with bariatric surgery and agreeing to undergo the intervention,with 3. given informed consent exclusion criteria: 1. unmeeting the above inclusion criteria.
a study of cin-107 in patients with uncontrolled hypertension

Conditions: Uncontrolled Hypertension

Summary: this is a phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of baxdrostat (also called cin-107) in the treatment of patients with uncontrolled hypertension. the primary objective was to demonstrate that treatment with baxdrostat for 8 weeks would lower the systolic blood pressure (sbp) in patients who were hypertensive despite taking one or two anti-hypertensive medications. participants were assigned to take placebo or baxdrostat once per day for 8 weeks while they continued taking the regular anti-hypertensive medications. at the end of the 8-week period, qualified patients could participate in part ii of the study and receive 2 mg baxdrostat for 4 weeks while they discontinued taking the background anti-hypertensive medication.


Eligibility criteria:
inclusion criteria: * is on a stable regimen of background antihypertensive agent(s) for at least 8 weeks and would be considered a candidate for an additional antihypertensive agent at the time of screening ; * has a mean seated systolic blood pressure (sbp) ≥ 140 mmhg or ≥ 130 mmhg if diabetic; * demonstrates ability to be adherent to the study drug and their anti-hypertensive medication during a run-in period * if taking an sglt2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and * agrees to comply with the contraception and reproduction restrictions of the study; exclusion criteria: * has a mean seated systolic blood pressure (sbp) ≥180 mmhg; * has a body mass index (bmi) \>50 kg/m2; * is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache); * is not willing or not able to discontinue an mra or potassium sparing diuretic as part of an existing antihypertensive regimen; * has documented estimated egfr \<30 ml/min/1.73m2; * has known and documented new york heart association stage iii or iv chronic heart failure; * has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening; * major cardiac surgery within 6 months before screening; * has chronic permanent atrial fibrillation; * has uncontrolled diabetes with glycated hemoglobin \>10% at screening; * has planned dialysis or kidney transplantation planned during the course of the study; * prior solid organ transplant and/or cell transplants; * sodium \<130 meq/l; * potassium \<3.5 meq/l; * potassium \>5 meq/l; * white blood cell count \>15 × e9/l or absolute neutrophil count \<1 × e9/l at screening; * is positive for hiv antibody, hepatitis c virus rna, or hepatitis b surface antigen; * has typical consumption of ≥14 alcoholic drinks weekly;
hifem technology for post-radical prostatectomy and post-holmium laser prostate surgery

Conditions: Holmium Laser Prostate Surgery; Radical Prostatectomy

Summary: the purpose of this study is to evaluate the efficacy of high-intensity focused electromagnetic (hifem) technology in improving the recovery time of urinary control and quality of life for male patients after radical prostatectomy (rp) and holmium laser prostate surgery (holep).


Eligibility criteria:
inclusion criteria: * subjects who are male * post-radical prostatectomy or post holep * experiencing urinary incontinence one-month post-rp * have the capacity to make their own medical decisions * able to complete the questionnaires and visits required. exclusion criteria: * subjects who are not male * not post-radical prostatectomy or post holep * neurologic disease * atonic or hypofunctional bladder (bladder contractility index (bci) \< 100; bci = pdetqmax+5qmax) * status post pelvic radiation * past surgical history of other gu surgeries * gross hematuria * concomitant use of medications that cause muscle relaxation or inhibition * indwelling foley catheter at time of treatment * documented urine leak * not experiencing urinary incontinence * do not have the capacity to make their own medical decisions * unable to complete the questionnaires provided.
application of platelet-rich plasma (prp) in reproductive medicine

Conditions: Premature Ovarian Insufficiency; Intrauterine Adhesion; Poor Ovarian Response; Repeated Implantation Failure; Thin Endometrium

Summary: female fertility is affected by many factors, such as ovarian function, fallopian tube patency, uterine environment, and mental state, among which the ovaries and endometrium are more important. in reproductive medicine, ovarian dysfunction, poor ovarian reaction, intrauterine adhesion, recurrent implantation failure, and thin endometrium are the five most common diseases that affect fertility. these five diseases lack effective treatment, and previous studies have shown that platelet-rich plasma is promising in treating these five diseases, so it is necessary to further explore the therapeutic effect and potential mechanism.


Eligibility criteria:
inclusion criteria: * premature ovarian insufficiency: ① women aged \>18 and \ 25iu/l (interval \>4 weeks) at least 2 times, or total antral follicles (afc) \<5, or anti-mullerian hormone (amh) \<1.1ng/ml. * poor ovarian response: ① advanced age (≥40 years) or other risk factors for poor ovarian response; ② poor ovarian response in previous ivf cycle, with ≤3 oocytes retrieved using conventional protocols; ③ decreased ovarian reserve (antral follicle count \<5\~7 or anti-müllerian hormone \<0.5\~1.1 ug/l). meeting any 2 of the above 3 criteria is sufficient. * intrauterine adhesion: ① diagnosed by hysteroscopy and scored ≥5 points according to the american fertility society criteria (1988); ② with symptoms such as reduced menstrual flow amenorrhea, periodic lower abdominal pain, infertility, or recurrent miscarriage; ③ adult women with the desire to conceive. * thin endometium: ①endometrial thickness \<7mm on ovulation day or on the day of human chorionic gonadotropin (hcg) injection, or \<7mm on progesterone conversion day when using conventional hormone replacement therapy, ②adult women with the desire to comceive. * repeated implantation failure: women under 40 years old who have failed to achieve clinical pregnancy after transplanting at least three high-quality embryos within three fresh or frozen cycles. high-quality embryos include: day 3 embryos (with ≥8 cells, evenly sized blastomeres, and \<10% fragmentation) and blastocysts (≥3bb). exclusion criteria: * alanine aminotransferase \> 3 times the normal upper limit or estimated glomerular filtration rate (egfr) \< 90 ml/min; * suffering from hemorrhagic diseases (such as hemophilia) or taking anticoagulant or antiplatelet drugs; * suffering from serious mental illness, cardiovascular and cerebrovascular diseases and malignant tumors; * suffering from diabetes with poor blood sugar control or other systemic diseases; * drug abuse, alcoholism or drug addiction; * participated in other interventional clinical studies within half a year; * poor compliance; * other circumstances that are not suitable for participating in the study.
exome analysis in hearing impaired patients

Conditions: Hearing Impairment

Summary: hearing impairment is the most frequent sensory deficit in humans and affects one newborn out of 500. the prevalence rises to 3,5/1000 in teenagers due to retarded forms. most of hearing impairments (about two thirds) have a genetic origin, with recessive, dominant or x-linked mode of inheritance. some rare forms can be linked to mitochondrial dna. molecular diagnosis (i.e. defining the molecular basis of the disease, genes and precise dna variants) is essential for the follow-up of patients and families. the project intends to perform exome sequencing on 30 samples of families presenting with hearing impairment. families have been included based on the genetic origin of the hearing impairment (familial cases) and the exclusion of the involvement of 74 known deafness genes. exome sequencing (sequencing of the coding regions of all known genes, about 22,000) in these cases may underly new gene/disease relationships.

exome sequencing will be performed of 10 trios that each include two affected and one non affected members of a family. filtering of variants will be performed based on frequency. for each trio, data will be analysed in parallel to follow segregation of the variant(s) in candidate genes. the selected candidate genes will be further characterized in order to ascertain their involvement in hearing function. finally, once these new genes are well defined as "deafness genes" , their screening will be added to existing diagnostic panels.

Eligibility criteria:
inclusion criteria: * families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype) exclusion criteria: - sporadic cases of hearing impairment, or resolved familial cases

Keywords: hearing impairment familial
peg-interferon added to an ongoing nucleos(t)ide based treatment in patients with chronic hepatitis b to induce decrease of hbs-antigen

Conditions: Chronic Hepatitis B

Summary: a prospective, randomised, open-label phase iib clinical trial assessing the effect of pegylated interferon alfa-2a(pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic hbeag-negative hepatitis b the primary objective of the trial is to investigate whether the add-on of pegylated interferon alfa-2a to a continued treatment with nucleos(t)ide analogues increases the percentage of patients who have significant decrease (≥ 1log10) of hbs antigen after 48 weeks. 170 patients with chronic hepatitis b, hbe antigen negative, already being treated with an oral antiviral regimen and having a nondetectable viral load for at least 12 months are included.


Eligibility criteria:
inclusion criteria: * chronic hepatitis b, hbe antigen negative * treatment with a stable oral antiviral treatment (not containing telbivudine) and a fully suppressed viral load for at least 12 months (below limit of detection in conventional hbv-pcr assays, i.e. \<116 iu / ml). * 18-70 ys * willingness and ability to give informed consent and to follow study procedures * willingness to use adequate contraception exclusion criteria: * contraindications against treatment with pegylated interferon, e.g. depression, uncontrolled epilepsy, autoimmune diseases, pregnancy, leukocytopenia or thrombocytopenia at screening, etc. * active alcohol or drug abuse * preexisting polyneuropathy

Keywords: chronic hepatitis b
long-term resveratrol and metabolism

Conditions: Pre-diabetes

Summary: the main objective of the study is to investigate if 6 months resveratrol supplementation can improve glucose tolerance in overweight/obese individuals. as secondary objectives we want to investigate whether resting energy metabolism, intra-hepatic lipid content, physical performance, body composition and quality of life change by 6 months resveratrol supplementation in these individuals.


Eligibility criteria:
inclusion criteria: * men aged 40-70 years and postmenopausal women aged 50-70 years * bmi: 27-35 kg/m2 * stable dietary habits: no weight gain or loss \> 5kg in the last three months * willingness to limit consumption of resveratrol-containing food products and willingness to refrain from using resveratrol containing supplements * subjects will only be included when the dependent medical doctor of this study approves participation after evaluating data obtained during screening exclusion criteria: * uncontrolled hypertension * hba1c \> 6.5% * previously diagnosed with type 2 diabetes * medication use known to interfere with glucose homeostasis/metabolism * current alcohol consumption \> 20 grams alcohol/day * subjects who do not want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study. * participation in another biomedical study within 1 month before the start of the intervention * any condition, disease or abnormal laboratory test result that, in the opinion of the investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk

Keywords: resveratrol diabetes mellitus, type 2 insulin resistance metabolic diseases glucose metabolism disorders
immunotherapy of tumor with autologous tumor derived heat shock protein gp96

Conditions: Liver Cancer; Pancreatic Adenocarcinoma

Summary: to evaluate the safety and effectiveness of autologous gp96 treatment of liver cancer and pancreatic adenocarcinoma


Eligibility criteria:
inclusion criteria: 1. able to read and understand the informed consent document; must sign the informed consent; 2. aged 18 to 75 years old , sex is not limited; 3. pancreatic cancer or primary liver cancer,must have undergone radical resection; 4. availability of at least 0.5 g tumor sample; 5. receiving the first gp96 autologous immunotherapy within 8 weeks of postoperation; 6. patients could not have received previous chemotherapy, radiation, or immunotherapy before 4 weeks of gp96 treatment； 7. ecog ≤1；life expectancy of at least 12 weeks 8. adequate bone marrow function including the absence of lymphopenia (anc \> 1,500/ mm3; hemoglobin \> 10g/dl ; platelet count \>100,000/mm3), adequate liver function (serum glutamic oxaloacetic transaminase/ aspartate aminotransferase \[ast\], alanine amino transferase \[alt\] \<2.5 times institutional upper limit of normals \[iulns\] and bilirubin (total) \<1.5 times iuln), and adequate renal function (bun and creatinine \<1.5 times iulns); 9. agree to surgical indications of heart \& lung and without the coagulation system disease; 10.negative pregnancy test for female patients of childbearing potential; 11.agree to use contraception or abstain from sexual activity from the time of consent through 3 month after the end of study drug administration. exclusion criteria: 1. unable to get the informed consent ; 2. patient not suitable for radical resection; 3. patients with active liver disease； 4. did not get enough tumor tissue ; 5. progression prior to vaccination as determined by the principal investigator; 6. rreceiving other anti-cancer therapy at the same time; 7. patient with allergic constitution; 8. unstable or severe intercurrent medical conditions; 9. current diagnosis of human immunodeficiency virus and patients with active uncontrolled infection; 10. patients with any systemic disease needed to be treated with immunosuppressant or corticosteroids; 11. any other cilical trials within 30 days pre-vaccination; 12. female patients who are pregnant or breastfeeding.